发明授权
US07309695B2 Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
有权
用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物
- 专利标题： Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
- 专利标题（中）： 用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物
-
申请号： US10703783申请日： 2003-11-06
-
公开(公告)号： US07309695B2公开(公告)日： 2007-12-18
- 发明人: Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
- 申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
- 申请人地址： JP
- 专利权人： Takashi Muramatsu
- 当前专利权人： Takashi Muramatsu
- 当前专利权人地址： JP
- 代理机构： Saliwanchik, Lloyd & Saliwanchik
- 优先权： JP10/251812 19980824
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; A61K48/00
摘要：
The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
公开/授权文献
信息查询
